Nicardipine Hydrochloride Granules Used for Antihypertensive Activity

Nicardipine hydrochloride, a calcium channel blocker, has demonstrated marked effectiveness in the management of hypertension by inducing vasodilation through relaxation of vascular smooth muscle. This study explores the antihypertensive potential of Nicardipine hydrochloride formulated as controlled-release granules—a novel alternative to conventional oral dosage forms. The granules are engineered to deliver a sustained therapeutic effect, aiming to improve bioavailability, prolong drug action, and enhance patient adherence. Formulation development involved careful selection of excipients and optimization of granulation techniques to ensure stability and consistent release kinetics. In preclinical hypertensive models, the Nicardipine granules produced a consistent and significant reduction in both systolic and diastolic blood pressure. Pharmacokinetic analysis revealed an extended duration of action compared to standard immediate-release tablets. This formulation strategy offers a promising, patient-friendly approach for long-term hypertension management. However, further clinical investigations are essential to validate its efficacy and safety in human populations over extended use.